新诊断前列腺癌患者[18F]NaF PET/CT骨转移风险分析
该回顾性单中心研究纳入734例新诊断前列腺癌患者,评估[18F]NaF PET/CT诊断骨转移的准确性。结果显示高危组骨转移检出率37%,而中危ISUP GG3组仅0.8%,敏感性0.90、特异性0.99。提示该检查对中危GG3患者临床价值有限。
要点
- 高危前列腺癌患者骨转移检出率37%,中危ISUP GG3组仅0.8%。
- [18F]NaF PET/CT诊断骨转移敏感性0.90、特异性0.99。
- 中危ISUP GG3患者常规骨影像检查的临床效用可能有限。
核心结论
- [18F]NaF PET/CT对新诊断前列腺癌骨转移诊断准确性高,但在不利中危且ISUP GG3患者中因患病率极低而临床效用有限。
研究设计与样本
- 回顾性单中心研究纳入734例连续新诊断前列腺癌患者,均行[18F]NaF PET/CT进行初始分期。
- 按欧洲泌尿外科学会风险分类,中危亚组仅限ISUP GG3患者。
- 以随访影像和临床数据为参考标准验证患者层面骨转移发现。
主要发现
- 734例中607例(83%)为高危,127例(17%)为中危ISUP GG3。
- 总体225例(31%)检出骨转移;高危组224例(37%),中危组仅1例(0.8%)。
- 中危组随访发现1例潜在假阴性。
- 在参考标准明确的689例中,敏感性0.90、特异性0.99。
关键数值与推荐
- 国际指南推荐对高危和不利中危前列腺癌患者评估骨转移,但推荐主要基于平面骨显像研究。
临床怎么用
- [18F]NaF PET/CT可用于新诊断前列腺癌骨转移检测,诊断准确性高。
- 对不利中危且ISUP GG3患者,因骨转移患病率极低,常规骨影像检查的临床效用可能有限。
局限性
- 回顾性单中心设计。
- 中危亚组仅限ISUP GG3患者,样本量较小(127例)。
- 参考标准基于随访影像和临床数据,可能存在不完整性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: International guidelines recommend assessment for bone metastases in patients with high-risk prostate cancer (PC) and those with unfavourable intermediate-risk disease. These recommendations are largely based on studies using planar bone scintigraphy. We aimed to assess the diagnostic accuracy of [18F]sodium fluoride ([18F]NaF) PET/CT in newly diagnosed PC. We also evaluated the clinical utility of routine bone imaging in patients with unfavourable intermediate-risk disease and International Society of Urological Pathology grade group (ISUP GG) 3. METHODS: This retrospective single-center study included 734 consecutive patients with newly diagnosed PC who underwent [18F]NaF PET/CT for primary staging. Patients were classified according to the current European Association of Urology risk classification, with the intermediate-risk subgroup restricted to patients with ISUP GG 3. All scan reports were retrospectively reviewed, and patient-level findings regarding bone metastases were validated against a reference standard based on follow-up imaging and clinical data. Sensitivity, specificity, and predictive values were calculated. RESULTS: Of the 734 patients, 607 (83%) had high-risk disease and 127 (17%) had intermediate-risk disease with ISUP GG 3. Overall, bone metastases were detected in 225 patients (31%). Among high-risk patients, 224 (37%) had bone metastases, whereas only 1 of 127 intermediate-risk patients (0.8%) had bone metastases on [18F]NaF PET/CT. Follow-up identified one additional potential false-negative case in the intermediate-risk group. Among patients with a conclusive reference standard (n = 689), sensitivity and specificity were 0.90 and 0.99, respectively. CONCLUSION: [18F]NaF PET/CT demonstrates high diagnostic accuracy for the detection of bone metastases in newly diagnosed PC. However, given the very low prevalence of bone metastases, its clinical utility in patients with unfavourable intermediate-risk disease and ISUP GG 3 appears limited.
引用
- Madsen C, Zacho HD, Bisbjerg R, et al. Risk of bone metastases on [18F]NaF PET/CT in 734 patients with newly diagnosed prostate cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42700249. doi:10.1007/s00259-026-08148-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。